My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Blueprint Medicines (BPMC)
NASDAQ:BPMC
BPMC nasdaq
United States
Blueprint Medicines

Blueprint Medicines Stock Analysis & Ratings

Blueprint Medicines Stock Analysis Overview

Smart Score
1
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Blueprint Medicines stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

BPMC

BPMC Stock Stats

Previous Close$101.34
Open$102.66
Bid95 x 5
Ask0 x 0
Today’s Range$100.02 - $103.38
52-Week Range$79.08 - $124.71
Volume241.14K
Average Volume491.65K
Market Cap$5.87B
Beta0.65
P/E Ratio16.8
EPS5.97
Earnings DateNov 02, 2021

Company Description

Blueprint Medicines

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Sector
Healthcare
Industry
Biotechnology
CEO
Jeffrey W. Albers
Employees
462
ISIN
US09627Y1091
Address
45 Sidney Street, Cambridge, MA, 02139, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

BPMC FAQ

What was Blueprint Medicines’s price range in the past 12 months?
Blueprint Medicines lowest stock price was $79.08 and its highest was $124.71 in the past 12 months.
    What is Blueprint Medicines’s market cap?
    Blueprint Medicines’s market cap is $5.87B.
      What is Blueprint Medicines’s price target?
      The average price target for Blueprint Medicines is $124.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $152.00 ,the lowest forecast is $81.00. The average price target represents 23.81% Increase from the current price of $100.15.
        What do analysts say about Blueprint Medicines?
        Blueprint Medicines’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
          When is Blueprint Medicines’s upcoming earnings report date?
          Blueprint Medicines’s upcoming earnings report date is Nov 02, 2021 which is in 14 days.
            How were Blueprint Medicines’s earnings last quarter?
            Blueprint Medicines released its earnings results on Jul 29, 2021. The company reported -$1.857 earnings per share for the quarter, missing the consensus estimate of -$1.846 by -$0.011.
              Is Blueprint Medicines overvalued?
              According to Wall Street analysts Blueprint Medicines’s price is currently Undervalued.
                Does Blueprint Medicines pay dividends?
                Blueprint Medicines does not currently pay dividends.
                What is Blueprint Medicines’s EPS estimate?
                Blueprint Medicines’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Blueprint Medicines have?
                Blueprint Medicines has 58,570,000 shares outstanding.
                  What happened to Blueprint Medicines’s price movement after its last earnings report?
                  Blueprint Medicines reported an EPS of -$1.857 in its last earnings report, missing expectations of -$1.846. Following the earnings report the stock price went up 5.982%.
                    Which hedge fund is a major shareholder of Blueprint Medicines?
                    Among the largest hedge funds holding Blueprint Medicines’s share is Farallon Capital Management, L.L.C.. It holds Blueprint Medicines’s shares valued at 99M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis